Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers

Triple-negative breast cancer (TNBC), an aggressive subtype lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, accounts for 10–20% of breast cancers and is characterized by high metastatic potential and poor survival outcomes. Despite advancements in chemotherapy, the 5...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Zi-Xin Wang, Ju-Hang Chu, Ya-Ru Wang, Lu-Yao Huang, Ming-Ping Qian
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-04-01
Edice:	Oncology Reviews
Témata:	biomarker-driven therapy combination therapy immune checkpoint inhibitors immunotherapy triple-negative breast cancer
On-line přístup:	https://www.frontiersin.org/articles/10.3389/or.2026.1802090/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!